IDEC-C2B8: IDPH completed patient accrual in its 150-patient Phase III open label, single-arm pivotal trial

IDEC Pharmaceuticals Inc. (IDPH), San Diego, Calif. Product: IDEC-C2B8 Indication: Non-Hodgkin's B cell lymphoma Status: IDPH completed patient accrual in its 150-patient Phase III open label, single...